Misuse of medicines in the European Union: a systematic review of the literature.
about
Opioid agonist treatment for pharmaceutical opioid dependent peopleOpioid agonist treatment for pharmaceutical opioid dependent peopleEvolving paradigms in the treatment of opioid-induced bowel dysfunctionHarmonizing post-market surveillance of prescription drug misuse: a systematic review of observational studies using routinely collected data (2000-2013).Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN).Opioid-induced constipation: pathophysiology, clinical consequences, and management.Prevalence and Incidence Trends for Diagnosed Prescription Opioid Use Disorders in the United KingdomFunctional validity of a judgment skills measure within the concept of health literacy for sleeping disorder patients.Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadoneAn overview of the patterns of prescription opioid use, costs and related harms in Australia.The total sale of prescription drugs with an abuse potential predicts the number of excessive users: a national prescription database study.Practice implications and recommendations for managing codeine misuse and dependence.Presentations due to acute toxicity of psychoactive substances in an urban emergency department in Switzerland: a case series.Estimating the health care burden of prescription opioid abuse in five European countriesThe Impact of Opioid Treatment on Regional Gastrointestinal Transit.How Resistant to Tampering are Codeine Containing Analgesics on the Market? Assessing the Potential for Opioid Extraction.Nonmedical Use of Antihistaminergic Anxiolytics and Other Prescription Drugs among Persons with Opioid Dependence.Presentations to an urban emergency department in Bern, Switzerland associated with acute recreational drug toxicity.Prevalence and Socio-Demographic Determinants of Tobacco, Alcohol, Substance Use and Drug Misuse in General Population in Turkey.Lessons learned in the abuse of pain-relief medication: a focus on healthcare costs.Safety issues around misuse of antiepileptics.Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world?Long-acting Preparations in Substance Abuse Management: A Review and Update.Substance abuse/dependence treatment: a European perspective.The Abuse Potential of Prescription Opioids in Humans-Closing in on the First Century of Research.Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.Which psychoactive substances are used by patients seen in the healthcare system in French overseas territories? Results of the OPPIDUM survey.Codeine use, dependence and help-seeking behaviour in the UK and Ireland: an online cross-sectional survey.Self-limiting non-medical pharmaceutical opioid use among young people in Sydney, Australia: An exploratory study.Medicines containing codeine: perspectives of medical professionals in the Republic of Ireland.Experiences of Codeine Use, Misuse and Dependence: Application of Liese and Franz's Cognitive Developmental Model of Substance Abuse.Factors influencing medication label viewing in Malaysia.Buprenorphine treatment for narcotic addiction: not without risks.Preference for brand-name buprenorphine is related to severity of addiction among outpatients in opioid maintenance treatment.Preventability of adverse effects of analgesics: analysis of spontaneous reports.Three-Year Follow-Up of Insomnia and Hypnotics after Controlled Internet Treatment for Insomnia.Non-medical prescription drug use (NMPDU) and poor quality of life in the Swedish general population.Do we have sufficient information to optimally inform regulatory or other policy decisions about medications containing codeine?
P2860
Q24185775-4CB9C107-69D5-4179-B882-A66BE789E5A4Q24194813-401CBEB0-37F8-4C00-82DB-6D8EE549D4A2Q26777692-A5288BD1-900A-482A-B68A-0078D70C5AA5Q30950812-01E830BD-F62F-4F09-8C15-056CFBC7B915Q31011586-C1D0C670-B1C1-4AAA-9EC8-D912973271ECQ33635040-5578AE87-4927-4608-9D0B-6DAFEA65580FQ33736179-D1A6821B-5122-4DA6-B79D-A6A70E3B34E4Q34412165-C00576B7-C355-46AB-9691-E5B444BC2290Q34481933-B2F346F2-C5BE-429F-9039-AB92D65CDD5FQ34570972-694AEB95-19F8-4C24-85F3-56700082D883Q35227943-E4777A6F-CED5-44E2-965A-4B6B3E1EBDEDQ35871497-E4593BDF-C9F9-4DD0-9262-7243267DFDECQ36031083-F1CCBD8B-3D4B-4661-8E77-F6C7622098B1Q36079375-F68DD6C5-EA63-4293-9A55-90C9D744D04EQ36762661-E25242E0-181E-4E4D-A9EE-3FC8BE247CAEQ37459006-123FFCB2-E903-4D41-B261-EEAC14C01B62Q37549535-89DC917A-7CDA-4682-9152-D6AABC661117Q37684273-CF302970-2BE9-46F8-8717-A45F4654648AQ37735569-6F19BFB1-ABBB-41FE-94DC-0EA184A96520Q38101985-1A1D79EB-E1C2-43D4-A052-DE0497A543DCQ38103947-C9853168-65D7-4A87-84B3-DD3BEBF1E0C5Q38108385-119FF5A8-0DC2-4F30-8557-2EF016F145C9Q38119942-AC222CEF-40A0-43A3-A1F4-2F76CDBC0D78Q38207160-42F5B72B-8B1C-4C83-85D3-FB0545A876F8Q38379235-C6FEBC23-375A-438A-A0DD-E6D09A26753BQ38632934-6A7F86CC-A749-4649-A95A-CF36C92AD48AQ38683620-70BD2530-22FB-40A2-B8B9-C8ACE025B4D9Q38799636-6ACC135F-9AAE-46DA-9A2C-CF705ECF46EAQ38825690-60D6F2C0-D4C6-4681-AC4B-F64616D3BBD6Q38853123-8C96BAAA-354A-4ED1-9D4D-B4812BCCB8CCQ38895082-30846199-50C2-49A5-A3A6-749CFA9C7DB1Q39030022-AE115EA6-7282-4021-934F-1360C436E27FQ39159904-E2463153-7B80-4711-AA16-0F362BAFD27BQ39608453-6CF92FD0-2D9A-431B-B8D7-557B147AF268Q40283005-F08F8971-801A-4D56-9852-49EB9ED4DB27Q40991270-C574DCCD-8351-41FC-BA29-4D4B08FA0912Q41305333-E7EB4C71-3896-4470-BB17-CE9EA2E18EE5Q41347079-2124FDA6-D5A2-4736-B5B7-C9CB79B2D358Q41478896-75EC1E1E-1B20-476E-9F6D-DEB6E88F8385Q44153501-78E44F2F-E54F-4987-BC5C-CC724BC97319
P2860
Misuse of medicines in the European Union: a systematic review of the literature.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Misuse of medicines in the European Union: a systematic review of the literature.
@ast
Misuse of medicines in the European Union: a systematic review of the literature.
@en
Misuse of medicines in the European Union: a systematic review of the literature.
@nl
type
label
Misuse of medicines in the European Union: a systematic review of the literature.
@ast
Misuse of medicines in the European Union: a systematic review of the literature.
@en
Misuse of medicines in the European Union: a systematic review of the literature.
@nl
prefLabel
Misuse of medicines in the European Union: a systematic review of the literature.
@ast
Misuse of medicines in the European Union: a systematic review of the literature.
@en
Misuse of medicines in the European Union: a systematic review of the literature.
@nl
P2093
P2860
P356
P1476
Misuse of medicines in the European Union: a systematic review of the literature.
@en
P2093
Alicia Casati
Roumen Sedefov
Tim Pfeiffer-Gerschel
P2860
P304
P356
10.1159/000337028
P577
2012-05-04T00:00:00Z